IGFBP2 and prostate carcinoma: Elevated plasma IGFBP2 levels correlate with malignancy risk in prostate cancer (71, 72) NSCLC studies link IGFBP2 overexpression to gefitinib resistance, reduced survival, and increased metastasis (73–75).